02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

(2002): Robenshtok E+, Isr Med Assoc J 4(7), 535 (from<br />

eyedrops)<br />

Injection-site irritation (>10%)<br />

*Note: Many of the above trade name drugs contain phenobarbital,<br />

scopolamine, hyoscyamine, hydrocodone, methenamine, etc.<br />

AURANOFIN<br />

(See GOLD <strong>and</strong> GOLD COMPOUNDS)<br />

AUROTHIOGLUCOSE<br />

(See GOLD <strong>and</strong> GOLD COMPOUNDS)<br />

AZACITIDINE<br />

Trade name: Vidaza (Pharmion)<br />

Indications: Myelodysplastic syndromes, refractory anemia<br />

Category: Antineoplastic; Cytosine analog<br />

Half-life: 48 ± 8 min<br />

Clinically important, potentially hazardous interactions<br />

with: None<br />

Reactions<br />

Skin<br />

Adverse effects (sic)<br />

(1991): Goldsmith SM+, Arch Dermatol 127(12), 1847<br />

Cellulitis (8%)<br />

Diaphoresis (10.5%)<br />

Edema (14.5%)<br />

Erythema (17%)<br />

Hematomas (9%)<br />

Herpes simplex (9%)<br />

Induration (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!